RESULTS: Of 18,484 samples obtained from 18,076 atrisk donors, 3 (1:6,025, 0.017%) donors showed seroreactivity by enzyme-linked immunosorbent assay and chemiluminescent immunoassay. All antibodypositive donors were born in Latin America. One of them also was positive for T. cruzi DNA. Eleven previous donations from this donor were subjected to look-back investigation, and five recipients were tested. All five recipients tested negative for T. cruzi antibodies.
CONCLUSION: Seroprevalence of T. cruzi was 0.017% among at-risk donors in Japan. Transfusion-transmitted infection of Chagas disease has not been confirmed to date. Screening for T. cruzi antibodies by targeting atrisk donors is an appropriate strategy for ensuring blood safety in Japan. C hagas disease is caused by the protozoan parasite Trypanosoma cruzi and is endemic in parts of Mexico and Central and South America (Latin America). T. cruzi is transmitted to mammalian hosts by the infestation of the body with feces from infected triatomine insect vectors (reduviid bugs) and by ingestion of contaminated food (e.g., acai palm fruit) in endemic areas. [1] [2] [3] This pathogen also is transmitted from mother to infant through the vertical route, and from T. cruzi-infected donors by transplantation or transfusion. [4] [5] [6] [7] Infected individuals are usually asymptomatic, although they sometimes develop short-term, localized swelling at the site of the bite and/or flulike symptoms. Lifelong, chronic persistence of parasitemia often occurs, and up to 30% of infected individuals will develop chronic Chagas disease, affecting the smooth muscle of the heart or gastrointestinal tract after 20 to 30 years. 1, 2, 8 Given the low quantities of T. cruzi parasites in peripheral blood in chronically infected individuals, the chronic phase often cannot be detected by T. cruzi antigen/DNA detection methods, instead requiring T. cruzi antibody detection methods. 9 Recently, due to an increase in the number of immigrants from Latin America and travelers to Latin America, Chagas disease has become a problem even in non-endemic countries. Cases of transfusion-transmitted infection (TTI) of Chagas disease have been reported in nonendemic countries, and thus blood centers in these countries have employed blood-screening systems to test samples for T. cruzi infection. [10] [11] [12] [13] [14] In North America (the United States and Canada) and Spain, 20 TTI cases have been reported; these cases were largely associated with platelet transfusions. 15 Screening for T. cruzi infection has suggested that at-risk donors for Chagas disease are mainly those born in Latin America and possibly those with a history of travel to Latin America. [10] [11] [12] [13] [14] Japan has a long history of relations with countries in Latin America; in the late 19th century, many Japanese people migrated to these countries, where they contributed to the development of the local societies. Recently, Japanese descendants from countries in Latin America have immigrated to Japan because of labor shortages in Japan. The Ministry of Justice of Japan reported that, from 2006 to 2016, between 230,000 and 280,000 people came from Latin America to live in Japan. 16 It is known that many immigrants from Latin America live in the regions of North Kanto and Tokai, both central areas of Japan. Moreover, T. cruziinfected persons are expected to be members of this immigrant group and to be active blood donors. Therefore, although there are no known insect vectors for Chagas disease in Japan, the possibility of TTI remains a concern; a previous study suggested that there were over 3000 T. cruziinfected individuals in Japan. 1, 17 Given the potential for Chagas disease in Japan, the Japanese Red Cross Society (JRCS) implemented a safety measure for the prevention of TTI of Chagas disease on October 15, 2012, such that blood provided by "at-risk" donors, defined as donors who themselves, or whose mothers, were born or raised in Latin America, or those with a history of travel to Latin America, is used only as a source of plasma derivatives, not of blood components. However, it is not known whether TTI of Chagas disease occurred before the implementation of this safety measure, and the risk of TTI of Chagas disease in Japan has not yet been evaluated, given that the seroprevalence of T. cruzi infection among at-risk blood donors has not been surveyed. The applicability in Japan of specific T. cruzi antibody detection tests also is unknown.
To clarify these issues, we first evaluated the limit of detection of a total of seven antibody detection tests using the International Standard, and the high limits of the detection tests also were evaluated using human specimens. Using the qualified tests, we then conducted an epidemiologic survey for T. cruzi antibodies among at-risk donors in Japan. The results of a retrospective study for T. cruzi antibody using repository samples obtained before the implementation of the safety measure also are described.
MATERIALS AND METHODS

Settings
The JRCS is responsible for all processes of the blood program in Japan from blood collection, processing, and testing through product supply. It has established 8 regional blood centers (Hokkaido, Tohoku, Kanto-Saitama [North Kanto], Kanto-Tokyo [South Kanto], Tokai-Hokuriku, Kinki, Chugoku-Shikoku, and Kyushu) and 47 local blood centers. 18 The JRCS handles about 5 million donations per year.
Starting in 1996, samples of all blood donations were placed in storage (for 11 years) to permit look-back studies for possible infectious diseases. 18 All 8 Japanese regional blood centers participated in this study.
Evaluation of limit of detection of T. cruzi antibody detection tests for screening among at-risk donors in Japan
The seven antibody detection tests used in this study are shown in Table 1 . The limit of detection of each antibody detection test was estimated using the serially diluted World Health Organization (WHO) International Standard. All testing, except for in-house indirect immunofluorescence assay (IFA), was performed according to the manufacturer's instructions. The in-house IFA was prepared using T. cruzi strain JRC-Tc2, which was isolated at our institution, from the blood of a Brazilian patient with Chagas disease. This T. cruzi parasite was assigned to discrete typing units (DTUs) TcII by phylogenetic analysis of the T. cruzi mitochondrial cytochrome oxidase subunit 2-encoding gene. 19, 20 Briefly, cultured T. cruzi parasites were adjusted to a density of 10 6 parasites/mL in chilled phosphate-buffered saline.
Parasites were then added to the wells of IFA slides (Matsunami Glass Ind., Ltd.), air-dried for 1 hour at room temperature, and fixed with cold acetone. The resulting IFA slides were preserved at −80 C until use. Each human plasma sample was diluted 80-fold with a blocking reagent (blockace, DS Pharma Medical, Inc.). Twenty microliters of each diluted sample were added to individual wells on T. cruzi-coated slides and incubated for 1 hour at 37 C. The slides were then washed with phosphate-buffered saline. Twenty microliters of anti-human immunoglobulin G fluorescent dye conjugate (Alexa Fluor 488, ThermoFisher Scientific; diluted 500-fold with blockace), as appropriate, were added to each well and incubated for 1 hour at 37 C. The For the evaluation of the specificity of T. cruzi antibody detection tests, 30 human plasma samples were used that had been evaluated by enzyme-linked immunosorbent assay (ELISA) and radioimmunoprecipitation assay for T. cruzi infections. 10 These were gifts from Dr. Susan Stramer at the American Red Cross. The breakdown was as follows: 15 of the 30 human samples were reactive to T. cruzi by ELISA and radioimmunoprecipitation assay. The remaining 15 human samples were negative by ELISA. Additionally, 20 human T. cruzi antibody-positive samples were purchased from SeraCare. In total, 35 T. cruzi antibodypositive and 15 T. cruzi antibody-negative samples were tested by ELISA (Trypanosoma cruzi Whole Cell Lysate Antigen ORTHO T. cruzi ELISA Test System, Ortho Clinical Diagnostics), chemiluminescent immunoassay (CLIA, ARCHITECT Chagas, Abbott), and enzyme strip assay (ESA).
Selection of at-risk donors and collection of blood samples among at-risk donors
At-risk donors were selected, and their blood samples were collected during two periods as follows.
1. From January 8, 2013, to August 21, 2016, every donor went through the following questionnaire: 1) Were you born or raised in Latin America (Central and South America including Mexico)? 2) Was your mother born or raised in Latin America? 3) Have you ever stayed in Latin America for a total of 4 weeks or longer? At-risk donors were defined as those who fulfilled one or more of these three conditions. Blood samples were collected from these donors after obtaining informed consent about testing for T. cruzi antibody by physicians.
2. From January 1, 2004, to October 14, 2012, at-risk donors were defined as those who fulfilled both of the following categories: 1) donor with a residence history in Latin America (Central and South America including Mexico) according to the record of travel history, and 2) donor whose donated blood had been processed to platelet concentrate (PC). The latter category was introduced on the basis of the fact that TTI of Chagas disease has occurred mainly by platelet transfusion. 15 The JRCS has obtained informed consent from all blood donors in Japan to test donated blood for infectious disease to ensure blood product safety. Repository blood samples derived from the atrisk donations were tested for T. cruzi antibody.
Laboratory tests for at-risk donor samples
Blood samples obtained from at-risk donors were tested for the detection of T. cruzi antibodies by ELISA. Positive samples were retested in duplicate by ELISA. Repeat reactive samples by ELISA then were confirmed by CLIA. In molecular testing for the detection of T. cruzi DNA, DNA was extracted from 1 mL of clotted blood with a DNA purification kit (QIAsymphony DNA MIDI Kit, Qiagen) and amplified for T. cruzi DNA by the TaqMan PCR method as previously described. 21 
Look-back investigation
Look-back investigation was conducted for patients transfused with blood components, except for plasma derivatives, processed from donations that tested positive for T. cruzi Volume 59, January 2019 TRANSFUSION 289
antibody by both ELISA and CLIA. Information about recipients of the blood products from positive donors was obtained from the relevant medical institution.
Ethics statement
This study was performed after ethical approval of the protocol by the JRCS Review Board (approval number: 2012-009).
Statistical analysis
The 95% confidence interval (CI) of the positive rate was evaluated using the normal approximation test.
RESULTS
Evaluation of limit of detection of T. cruzi antibody detection tests
Evaluation of the limit of detection of a total of seven detection tests was performed using the serially diluted WHO International Standard. As shown in Table 1 The specificities of ELISA, CLIA, and ESA, which had high limits of detection, were evaluated using 35 T. cruzi antibody-positive samples. All of the anti-T. cruzi-positive samples showed reactivity with these assays. Additionally, all three assays exhibited no reactivity against 15 T. cruzi antibody-negative samples.
Survey of T. cruzi-infected individuals among atrisk blood donors in Japan
Between January 8, 2013, and August 21, 2016, the JRCS collected blood from 17,038,260 blood donors. Among these donors, 13,298 (0.078%) were identified as at-risk donors (Table 2 ). This at-risk donor population consisted of 73.1% men and 26.9% women ( Table 2) . Median age was 39 years. The largest proportion of donors (31.4%) was from the Kanto-Tokyo (South Kanto) region.
Of these donations, 3888 were obtained from 3813 (28.7% of at-risk donors, 0.023% of all donors) donors who were born or raised in Latin America (Table 3) . Furthermore, 514 donations were obtained from 503 (3.8% of at-risk donors, 0.003% of all donors) donors who had a mother from Latin America. The remaining 9304 donations were obtained from 8982 (67.5% of at-risk donors, 0.053% of all donors) donors who had stayed in Latin America for 4 weeks or longer.
A total of 13,706 samples obtained from 13,298 at-risk donors were tested for T. cruzi antibodies. Twelve (0.088% of at-risk donors) samples were repeatedly positive by ELISA (Trypanosoma cruzi Whole Cell Lysate Antigen ORTHO T. cruzi ELISA Test System, Ortho Clinical Diagnostics). Three (0.022% of at-risk donors) of these 12 samples were confirmed to be antibody-positive by CLIA; two were from men in their 40s and one was from a woman in her 20s. One of the three samples was collected at the KantoSaitama (North Kanto) regional blood center, and the other two were collected at Tokai-Hokuriku regional blood centers ( Table 2 ). All antibody-positive individuals were born or raised in Latin America, one in Brazil, and two in Bolivia. Additionally, one of the three antibody-positive samples was positive for T. cruzi DNA (C T value = 39.3).
Most at-risk donors who answered positively to question 1 or 2 were born or raised in Brazil (71.27%) ( Table 3) , and one such donor was T. cruzi antibody-positive (1:3076, 0.03%; 95% CI, 0.006-0.18%) ( Table 3) . Although the proportion of donors who were born or raised in Bolivia was low (2.18%), two such donors were confirmed to be T. cruzi antibody-positive (1:47, 2.13%; 95% CI, 0.59-7.43%). Most at-risk donors with a travel history to Latin America also had stayed in Brazil (data not shown), and all samples from donors in this question were antibody negative. Antibody-positive donors accounted for 0.07% (1:1439; 95% CI, 0.024-0.2%) of all donors who were born or raised in Latin America, 0.023% (3 of 13,298; 95% CI, 0.008-0.066%) of all at-risk donors, and 0.000018% of all donors who donated during the survey period.
A total of 4778 (0.01%) at-risk donors who donated from January 1, 2004, to October 14, 2012, were identified from 45,796,653 donors using the computer system (Table 2 ). In this survey period, the at-risk donor population consisted of 63.4% men and 36.6% women ( Table 2) . Median age was 35 years. The plurality (27.1%) of at-risk donors came from Kanto-Tokyo (South Kanto). The corresponding repository samples from these donations were tested for T. cruzi antibodies by ELISA. All of these samples were negative for T. cruzi antibodies.
Look-back investigation
Two of the three antibody-positive donors were the first donations. The remaining donor who tested positive for both T. cruzi antibody and T. cruzi DNA had previously donated blood nine times, and 11 blood products manufactured from the donor's blood, including 9 red blood cell (RBC) products and 2 fresh frozen plasma products, had been transfused into patients. All 9 of the repository samples were positive for T. cruzi antibody. Of the 11 recipients, 5 were deceased, 5 were alive, and one did not consent to antibody testing. The 5 recipients available for testing were all negative for T. cruzi antibodies.
DISCUSSION
This study demonstrated the prevalence of T. cruzi antibody among at-risk donors in Japan. First, appropriate T. cruzi antibody detection tests were selected through the evaluation of assay limit of detection and specificity using the WHO International Standard and human specimens. Using the selected tests, we screened for T. cruzi antibody among the total of 18,076 at-risk donors from the two study periods combined. Three donors were identified as being T. cruzi antibody-positive (0.017%; 95% CI, 0.006-0.049%). Only one of the three donors was a repeat donor and T. cruzi DNApositive as well. Eleven blood products manufactured from this individual's blood had been transfused. By look-back investigation, five recipients of such products were available and willing to be tested for T. cruzi antibody. None of these recipients were shown to be antibody positive.
Several studies have evaluated antibody detection tests for T. cruzi. 22, 23 However, none of these studies addressed the tests for limit of detection using the WHO International Standard. Therefore, we evaluated the limit of detection of seven kinds of antibody detection tests using the WHO International Standard. CLIA demonstrated the highest limit of detection among the assays, as shown using both the TcI and TcII International Standards. ELISA and ESA also exhibited high limits of detection. Furthermore, our evaluation showed high specificities for these kits, consistent with the results reported in previous studies. [24] [25] [26] The limit of detection of the in-house IFA was higher for TcII than for the TcI International Standard. This result was consistent with the fact that the target parasite used for the in-house IFA originated from a T. cruzi strain of discrete typing units TcII that is the major strain distributed in South America, in contrast to the discrete typing units TcI that is present in Mexico. 20 Our epidemiological survey showed that, among at-risk donors in Japan, antibody-positive individuals were limited to those who were born or raised in Latin America. Conversely, none of the donors who had temporarily stayed in Latin America for 4 weeks or longer exhibited seropositivity. We generated a table based on the combination of results from the present study and previous reports from various countries (Table 4) . [10] [11] [12] [13] [14] Our results showed that 0.017% of at-risk donors were antibody positive. This seroprevalence of T. cruzi infection among at-risk blood donors in Japan was higher than those in England and France but was lower than those in Canada and Spain. Notably, positive donors identified in England and France were limited to individuals who were born or raised in Latin America. 11, 13 In addition, the majority of positive donors identified in Canada (11 of 13) and Spain (10 of 11) were also born in Latin America. 12, 14 Thus, our results that all positive donors in Japan were born or raised in Latin America are in line with the results of previous studies.
The issue of TTI for T. cruzi did not receive much attention from Japanese physicians until 2012, when the JRCS started processing blood obtained from at-risk donors only into plasma derivatives. However, the identification of T. cruzi-infected individuals among blood donors via a JRCS epidemiologic survey raised concerns among physicians regarding blood safety in the context of TTI of Chagas disease. 27 A special committee of the Japanese Ministry of Health, Labour and Welfare proposed that the JRCS perform a look-back investigation of all recipients of blood components obtained from at-risk donors. The rationale behind this decision was that Chagas disease represents a lifelong chronic illness that could be medicated before the development of end-stage disease. The JRCS accordingly identified at-risk donors using the record of overseas residence and travel history, and whether the donated blood had been used to generate PC; the JRCS expected that this category of donors would include most donors who had a risk of transmitting T. cruzi via transfusion. Based on these criteria, we identified 4778 at-risk donors together with their repository blood samples back to January 2004. All of the tested repository samples were negative for T. cruzi antibodies. The proportion of identified at-risk donors during 2004-2012 (0.01% of all donors) was lower than the proportion during the later period of 2013-2016 (0.078% of all donors). This difference between the two survey periods likely reflects the difference in the criteria for identifying atrisk donors: in the former period, only donors for plateletpheresis were included, which also explains the absence of seropositives in the former study because most donors from Latin America donate whole blood, not platelets, and Japanese with a travel history to Latin America accounted for the majority of the at-risk group in the former study.
Platelet products have been identified as primary sources of T. cruzi transmission in nonendemic countries. 15 It has been reported that higher parasitic load is observed in PC compared with plasma and peripheral whole blood from T. cruzi antibody-positive individuals. 28 Moreover,
Moraes-Souza and colleagues reported that leukofiltration effectively decreased the T. cruzi load in infected blood. 29 Similarly, we have observed that leukofiltration reduces not only T. cruzi load but also proliferative capacity, and that These in vitro results and the absence of T. cruziseropositive donations for PC in our study indicate that the risk of Chagas disease transmission through Japanese transfusion products was extremely low even before 2012 when the exclusive application of at-risk blood to plasma derivatives started. Notably, the ongoing hemovigilance and blood sample storage practiced by the JRCS made it possible to perform the present retrospective study. 18 Thus, these systems are very effective for evaluating the safety of blood transfusion.
Our study was limited to individuals with known potential for T. cruzi infection (at-risk donors) but did not cover all donors in Japan. In the United States, in fact, all donors are tested for T. cruzi infection. 10 However, the strategy for the prevention of TTI for Chagas disease in non-endemic areas should differ among areas depending on the geography, population structure, or environment of the area. This stringent strategy in the United States was introduced mainly because of the larger number of immigrants from Latin America entering the United States compared to those entering Japan and other countries, as well as the existence of vectors and reservoirs in the southern half of the United States, necessitating the screening of all blood donors in the country. 30, 31 Even in the United States, however, blood donors who are antibody positive are almost all immigrants from Latin America. Thus, the present work, in combination with previous studies in non-endemic countries, indicates that our strategy for the prevention of TTI of T. cruzi that focused on only at-risk donors is reasonable and efficient in Japan.
11-14
Our results serve as a theoretical basis for the current JRCS strategies for the prevention of TTI for T. cruzi. These strategies include the following three points: 1) Donors who were born or raised in Latin America, donors whose mother or maternal grandmother were born or raised in Latin America, or donors who have a travel history of 4 continuous weeks or longer in Latin America should be tested for the presence of T. cruzi antibodies; 2) blood obtained from antibody-negative donors can be processed into blood components and plasma derivatives; and 3) individuals should be deferred from blood donation within 6 months after leaving Latin America. Additionally, all blood components in Japan are leukoreduced. Thus, the risk of TTI of Chagas disease in Japan is considered to be very low under the current strategies.
It is necessary to raise awareness of Chagas disease among travelers to Latin America so that these travelers can prevent themselves from acquiring Chagas disease, for example, by avoiding contact with triatomine bugs and consumption of contaminated food (e.g., acai palm fruit) while staying in endemic areas. On the other hand, clinicians in Japan, mainly cardiologists and gastroenterologists, need to increase their awareness of Chagas disease, which is historically a little-known disease in Japan.
In conclusion, three of 18,076 (0.017%) at-risk blood donors in Japan tested positive for T. cruzi antibody. All three had been born and raised in Chagas disease-endemic countries. This fact indicates that there is an ongoing risk of TTI of T. cruzi in the non-endemic country of Japan, although no TTI case in Japan has been confirmed to date. To address this challenge, the JRCS initiated, on August 22, 2016, a program of screening at-risk donors for the presence of T. cruzi antibodies.
